A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses - American Association for Cancer Research (AACR)
After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some of the precancerous lesions shrank or stopped growing.
Comments